Inebilizumab

Tax included
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
MedChemExpress 
HY-P99113

Data sheet

Size
Multiple sizes
Reactivity
ADC Cytotoxin; CD19
Application
COVID-19-immunoregulation
CAS
1299440-37-1